Journal ArticleOPEN ACCESS

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

  • Bröckelmann P
  • Goergen H
  • Keller U
  • et al.
JAMA Oncology (2020) 6(6) 872
DOI: 10.1001/jamaoncol.2020.0750
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This phase 2 randomized clinical trial assesses the efficacy of concomitant and sequential treatment with nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) for patients with early-stage unfavorable Hodgkin lymphoma.

Cite

CITATION STYLE

APA

Bröckelmann, P. J., Goergen, H., Keller, U., Meissner, J., Ordemann, R., Halbsguth, T. V., … Engert, A. (2020). Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. JAMA Oncology, 6(6), 872. https://doi.org/10.1001/jamaoncol.2020.0750

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free